| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_985e586742507c77adffd57be9bc530e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-453
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D407-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 |
| filingDate |
2006-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2012-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09a97c39e5410c28f40632b430232431
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4467483d0537ac217c1c2e10688383d9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d2967d3de5760bb1177a54f39985465c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc81a24c51d584d148ebe7de06fadb76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87d04b5860ed15415dcb3d1436eeb339
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da2cb9e2ea0adc719691da30fb2f2002
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e21d2ecab2e00408e9a724f47f97244
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_99abcff53bd058e26af6f89063c0f349 |
| publicationDate |
2012-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-101356156-B |
| titleOfInvention |
Aspartic protease inhibitors |
| abstract |
The present invention is directed to aspartic protease inhibitors. Certain aspartic protease inhibitors of the invention can be represented by the following structural formula or a pharmaceutically acceptable salt thereof. The present invention is also directed to pharmaceutical compositions comprising the disclosed aspartic protease inhibitors. The present invention is further directed to methods of antagonizing one or more aspartic proteases in a subject in need thereof, and methods for treating an aspartic protease mediated disorder in a subject using the disclosed aspartic protease inhibitors. |
| priorityDate |
2005-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |